Silence Therapeutics (SLN) Corporate presentation summary

Strategic vision and technology

• Focus on silencing disease genes using proprietary siRNA technology for precision medicines.

• siRNA therapies are designed for high specificity, durability, reversibility, and broad gene targetability.

• Proprietary chemical modifications and linkers enhance siRNA stability and enable targeted delivery, especially to liver cells via GalNAc ligands.

• Operations span the US, UK, and Germany, covering drug discovery, design, and clinical development.

Pipeline and clinical progress

• Lead asset divesiran targets polycythemia vera (PV), showing robust efficacy, durable response, and favorable safety in Phase 1.

• Phase 2 study of divesiran in PV is fully enrolled, with topline results expected in Q3 2026.

• SLN312 (ANGPTL3) for dyslipidemia demonstrated robust, dose-dependent efficacy and safety in Phase 1; global rights to revert after Phase 1.

• SLN365 (GPR146) and SLN098 (INHBE) are advancing in preclinical stages for HoFH and obesity, respectively, with IND filings targeted for 2027.

Clinical data highlights

• Divesiran reduced phlebotomy frequency, hematocrit, and hemoglobin in PV patients, with sustained hepcidin increases and no dose-limiting toxicities.

• SLN312 achieved substantial reductions in ANGPTL3 and atherogenic lipoproteins, supporting infrequent dosing.

• SLN365 showed >80% mRNA knockdown and significant cholesterol/triglyceride reductions in preclinical models.

• SLN098 achieved >70% INHBE knockdown in primates, with preclinical obesity model data expected in 2Q 2026.